biostudies-literatureUnknown28(3)Yadav A<h4>Objectives</h4>The polyol pathway plays an important pathophysiological role in diabetic-related ocular complications, including cataracts, one of the major causes of ocular blindness. The current paper investigated the protective effects of plumbagin against diabetogenic cataract formation, focusing on exploring its possible mechanism of action.<h4>Methods</h4>The study investigates antioxidant activity, aldose reductase inhibitory activity, and anticataract activity in experimental pharmacological models. In the <i>ex-vivo</i> study, goat lenses were incubated in artificial aqueous humor with high concentrations of glucose (55.5 mM) and plumbagin (20, 50, and 100 µg/mL), which was assessed against cataract control lenses.<h4>Results</h4>The <i>in-vitro</i> study showed that plumbaginJournal of pharmacopuncture191-200https://www.ebi.ac.uk/biostudies/studies/S-EPMC12464086biostudies-literaturePlumbagin Protects Diabetogenic Cataract Formation by Mitigating Lens Aldose Reductase and Oxidative Stress.PMC12464086Nirmalkar UChoudhary RPaul SDYadav ARam AfalsePlumbagin Protects Diabetogenic Cataract Formation by Mitigating Lens Aldose Reductase and Oxidative Stress.<h4>Objectives</h4>The polyol pathway plays an important pathophysiological role in diabetic-related ocular complications, including cataracts, one of the major causes of ocular blindness. The current paper investigated the protective effects of plumbagin against diabetogenic cataract formation, focusing on exploring its possible mechanism of action.<h4>Methods</h4>The study investigates antioxidant activity, aldose reductase inhibitory activity, and anticataract activity in experimental pharmacological models. In the <i>ex-vivo</i> study, goat lenses were incubated in artificial aqueous humor with high concentrations of glucose (55.5 mM) and plumbagin (20, 50, and 100 µg/mL), which was assessed against cataract control lenses.<h4>Results</h4>The <i>in-vitro</i> study showed that plumbagin2025-01-01T00:00:00Z2025 Sep2026-06-03T21:37:03.516Z2026-05-02T03:07:58.108ZS-EPMC124640864101887610.3831/KPI.2025.28.3.191